Biohit Oyj B

Biohit Oyj B

BIOBV · HE · Healthcare / Medical Devices

2.11EUR-0.04 (-1.86%)

Price History

Full chart

Market Stats

Previous Close2.15
Open2.13
Day Range2.11 – 2.17
52-Week Range2.20 – 3.78
Volume4.18K
Market Cap36.04M
P/E (TTM)11.85
Forward P/E14.06
EPS0.20
Dividend Yield0.00%
Beta0.57
50-Day Avg2.56
200-Day Avg2.71

About

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company offers GastroPanel quick test NT, a rapid and quantitative immunochromatographic test for the detection of Helicobacter pylori and atrophic gastritis; GastroPanel test, a blood test for diagnosis of the function and structure of stomach mucosa; GastroSoft, a software application designed to assist clinicians and general practitioners in interpreting GastroPanel test results; and GP Reader NT for the quantitative determination of various analytes in human samples. It also provides BIOHIT active B12 (HoloTC) test, BIOHIT total 25OH vitamin D test, and BIOHIT Calprotectin; BIOHIT ColonView quick test for detection of fecal occult blood (FOB) in stool samples; BIOHIT Celiac quick test, a qualitative in vitro immunochromatographic test aiding in diagnosis of celiac disease; BIOHIT H. pylori UFT300 and H.pylori tests for the diagnosis of H,pylori infection; lactose intolerance quick test kit; and Gluten Immunogenic Peptides test. In addition, it offers Acetium acetaldehyde binding products, such as the Acetium lozenge to help quit smoking and Acetium capsule for the protection of the stomach. Further, the company provides monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. Additionally, it offers BIOHIT FAEX sample system for the collection and handling of stool samples. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOProf. Osmo Antero Suovaniemi M.D., Ph.D.
  • Employees47
  • HeadquartersLaippatie 1, Helsinki, Finland, 00880, Finland
  • Websitehttps://www.biohithealthcare.com

Leadership

  • Prof. Osmo Antero Suovaniemi M.D., Ph.D.Founder, Deputy CEO, Member of Scientific Advisory Board & Director · b. 1943
  • Mr. Jussi HahtelaPresident & CEO · b. 1973
  • Mr. Jussi SorvoChief Financial Officer · b. 1990
  • Ms. Kati PiironenChief Technology Officer · b. 1991
  • Mr. Ville SuovaniemiHead of Global Sales & Marketing
  • Mr. Yulia KubachevaHead of Diagnostics Department - Biohit Russia
  • Graham Johnson B.Sc.Managing Director of Biohit Healthcare Ltd - UK · b. 1977

Financials

Income Statement

Currency: EUR2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue144.17M25.55M25.35M26.26M26.70M28.66M31.41M32.75M34.80M35.37M40.04M39.92M2.05M3.45M4.36M6.05M8.20M8.98M9.93M10.05M7.12M9.36M10.95M13.08M14.30M15.70M
Growth (%)--82.28%-0.75%+3.57%+1.69%+7.33%+9.59%+4.28%+6.27%+1.61%+13.23%-0.30%-94.87%+68.55%+26.39%+38.69%+35.43%+9.57%+10.60%+1.22%-29.14%+31.42%+16.99%+19.40%+9.36%+9.79%
Cost of Revenue----5.58M5.68M6.42M6.70M6.68M6.47M8.20M9.58M1.32M1.70M1.92M2.85M3.99M3.34M3.49M3.38M3.17M3.45M3.84M4.61M5.00M9.60M
Gross Profit----21.12M22.98M24.98M26.05M28.12M28.89M31.84M30.34M728.00K1.75M2.44M3.20M4.21M5.64M6.44M6.67M3.96M5.91M7.11M8.46M9.30M6.10M
Gross Margin----79.11%80.17%79.54%79.55%80.80%81.70%79.52%75.99%35.55%50.72%55.90%52.83%51.31%62.81%64.86%66.33%55.57%63.18%64.93%64.73%65.03%38.85%
Operating Expense----20.87M23.01M25.13M26.51M26.81M27.70M31.33M-13.92M5.31M7.61M6.94M6.10M7.56M-716.00K8.41M8.04M7.13M7.39M5.98M6.64M6.70M2.90M
Operating Income-237.00K--251.00K-33.00K-143.00K-458.00K1.31M1.19M507.00K44.26M-4.59M-5.86M-4.50M-2.90M-3.36M6.36M-1.97M-1.37M-3.17M-1.48M1.13M1.82M2.60M3.20M
Operating Margin-0.93%--0.94%-0.12%-0.46%-1.40%3.78%3.36%1.27%110.87%-223.93%-169.76%-103.23%-47.93%-40.95%70.79%-19.79%-13.67%-44.57%-15.81%10.31%13.96%18.18%20.38%
EBITDA----1.81M1.67M1.62M1.68M3.38M3.28M2.59M-1.34M-3.26M-5.65M-4.06M-2.58M-2.92M7.41M-188.00K791.00K-1.25M692.00K1.61M2.69M3.50M3.70M
EBITDA Margin----6.77%5.82%5.15%5.13%9.72%9.27%6.47%-3.36%-159.03%-163.76%-93.03%-42.65%-35.62%82.56%-1.89%7.87%-17.56%7.39%14.69%20.56%24.50%23.57%
Net Income-----169.00K-226.00K-839.00K-1.50M897.00K387.00K61.00K37.71M-3.66M-5.92M-1.16M-2.92M-3.29M6.14M-2.14M-1.42M-3.31M-1.50M601.00K1.85M2.60M2.74M
Net Income Margin-----0.63%-0.79%-2.67%-4.59%2.58%1.09%0.15%94.46%-178.52%-171.41%-26.61%-48.21%-40.21%68.37%-21.58%-14.09%-46.50%-16.02%5.49%14.16%18.18%17.44%
R&D-2.11M1.81M1.45M1.30M1.63M1.69M1.64M1.65M1.99M2.09M-970.00K1.06M2.07M2.04M1.97M1.20M1.29M1.23M1.04M1.22M1.24M1.17M-1.32M
R&D as % of Total Revenue-8.28%7.13%5.51%4.87%5.69%5.38%5.02%4.74%5.62%5.22%-47.36%30.79%47.38%33.68%24.01%13.36%12.99%12.26%14.64%13.02%11.30%8.97%-8.43%
Interest Expense0000289.00K358.00K451.00K513.00K741.00K893.00K782.00K708.00K312.00K4.00K3.00K3.00K06.00K3.00K12.00K14.00K9.00K289.00K131.00K300.00K100.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.08%1.25%1.44%1.57%2.13%2.53%1.95%1.77%15.23%0.12%0.07%0.05%0.00%0.07%0.03%0.12%0.20%0.10%2.64%1.00%2.10%0.64%

Balance Sheet

Currency: EUR2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets146.42M25.00M22.41M21.88M22.76M27.85M27.32M27.34M27.11M27.40M29.38M71.47M40.01M28.30M14.51M11.73M12.99M18.89M17.89M17.37M10.78M9.61M11.02M12.92M15.50M19.80M
Total Liabilities48.39M8.66M7.52M7.77M8.62M13.60M13.90M15.50M14.62M14.65M16.38M18.63M4.51M5.85M1.83M1.42M2.24M1.65M2.00M2.79M2.07M2.31M3.56M3.49M3.30M4.87M
Total Equity97.73M16.22M14.82M14.04M14.14M14.25M13.41M11.84M12.49M12.75M13.00M52.85M35.49M22.45M12.68M10.31M10.75M17.24M15.89M14.58M8.70M7.30M7.46M9.43M12.30M14.90M
Cash17.93M2.46M1.37M1.05M1.30M1.75M850.00K1.11M1.31M1.58M1.66M47.91M248.00K467.00K608.00K723.00K597.00K1.34M1.38M1.32M1.04M1.10M2.12M3.03M3.70M3.50M
Total Debt----4.11M8.16M7.70M9.13M9.09M8.97M9.46M4.91M384.00K384.00K256.00K128.00K-76.00K59.00K287.00K945.00K221.00K943.00K702.00K600.00K1.59M
Net Debt----2.82M6.42M6.85M8.02M7.78M7.39M7.81M-43.01M136.00K-83.00K-352.00K-595.00K-597.00K-1.26M-1.32M-1.04M-93.00K-881.00K-1.18M-2.33M-3.10M-1.91M

Cash Flow

Currency: EUR2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow5.34M1.88M-863.00K2.24M605.00K100.00K1.04M1.19M2.80M1.96M4.96M-8.89M-4.44M-3.44M-3.15M-2.46M-943.00K-93.00K83.00K-25.00K-444.00K1.85M902.00K586.00K-700.00K
Investing Cash Flow-----2.14M-5.10M890.00K-2.13M-751.00K-1.90M-1.88M43.39M-20.52M14.63M12.94M2.89M2.52M1.20M4.00K-138.00K-35.00K760.00K-625.00K192.00K80.00K1.20M
Financing Cash Flow2.63M-1.03M-148.00K3.78M-894.00K1.37M-283.00K-596.00K-109.00K-2.14M-18.26M-9.97M-9.37M357.00K-128.00K504.00K131.00K-10.00K-222.00K-266.00K-186.00K-199.00K-230.00K-300.00K
Capital Expenditure28.63M2.17M1.73M1.14M2.13M1.68M1.80M2.06M1.23M2.02M1.78M4.07M281.00K475.00K401.00K223.00K92.00K170.00K15.00K46.00K15.00K33.00K59.00K248.00K400.00K600.00K
Free Cash Flow----108.00K-1.07M-1.70M-1.02M-40.00K776.00K183.00K888.00K-9.17M-4.92M-3.84M-3.37M-2.55M-1.11M-108.00K37.00K-40.00K-477.00K1.79M654.00K200.00K-1.30M
Dividends Paid------------13.61M10.02M9.99M-----------
FCF to OCF----4.83%-177.69%-1696.00%-98.27%-3.37%27.75%9.33%17.91%103.16%110.69%111.67%107.09%103.74%118.03%116.13%44.58%160.00%107.43%96.81%72.51%34.13%185.71%
Dividend Paid to FCF-------------148.39%-203.68%-260.45%-----------

Earnings

Report DateFeb 15, 2005Nov 4, 2005Feb 17, 2006May 5, 2006Aug 4, 2006Feb 16, 2007Nov 2, 2007Feb 15, 2008Nov 7, 2008Feb 13, 2009May 8, 2009Aug 7, 2009Nov 6, 2009Feb 12, 2010May 7, 2010Aug 6, 2010Nov 5, 2010Mar 1, 2011Apr 28, 2011Aug 18, 2011Oct 20, 2011Apr 26, 2012Aug 16, 2012Oct 25, 2012Feb 27, 2013Apr 25, 2013Aug 8, 2013Oct 24, 2013Feb 27, 2014May 5, 2014Aug 21, 2014Oct 23, 2014Feb 26, 2015May 7, 2015Aug 20, 2015Oct 22, 2015Feb 25, 2016Feb 28, 2018Jun 30, 2018Feb 20, 2019Jun 30, 2019Dec 31, 2019Jun 30, 2020Dec 31, 2020Jun 30, 2021Dec 31, 2021Jun 30, 2022Dec 31, 2022
EPS Estimate0.02-0.010.010.010.01-0.010.01--0.01-----------0.02---------------------------
EPS Actual-0.300.010.02-0.02-0.03-0.01-0.02-0.030.040.06-0.010.00-0.020.050.010.01-0.020.000.00-0.010.04-0.07-0.09-0.06-0.06-0.07-0.18-0.07-0.120.16-0.09-0.06-0.09-0.06-0.03-0.01-0.10-0.07-0.07-0.08-0.04-0.05-0.15-0.07-0.07-0.030.06-0.02
Surprise-1600.00%200.00%100.00%-300.00%-400.00%0.00%-300.00%-500.00%-----------100.00%---------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----------Pre-market---------------------------

Key Statistics & Ratios

Market Cap36.04M
Enterprise Value34.39M
Trailing P/E11.85
Forward P/E14.06
PEG Ratio7.04
Price / Sales2.23
Price / Book2.20
EPS0.20
Book Value1.07
Revenue (TTM)16.13M
Gross Profit (TTM)11.25M
EBITDA3.43M
Profit Margin19.45%
Operating Margin19.23%
Return on Equity21.42%
Return on Assets10.94%
Shares Outstanding12.23M
Shares Float7.17M
Beta0.57
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20141×
0.72Apr 15, 2014
20131×
0.50Apr 9, 2013
20121×
0.20Apr 12, 2012